Aanand D Naik1, Tim T Issac, Richard L Street, Mark E Kunik. 1. Houston Center for Quality of Care and Utilization Studies, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA. anaik@bcm.tmc.edu
Abstract
BACKGROUND: Observational studies routinely describe a significant gap between rates of blood pressure control in routine diabetes care compared with those achieved in randomized controlled trials (RCTs). METHODS: We performed a systematic review of the literature to identify co-maneuvers used in RCTs, defined as ancillary activities or agents administered before, during, or immediately after the main agent under investigation (ie, principal maneuver), but not effectively translated to routine diabetes care. We searched multiple databases for RCTs evaluating the efficacy of treatments for hypertension control in adults with type 2 diabetes mellitus. We considered only phase III human studies of interventions that achieved blood pressure control and scrutinized all elements related to the implementation of the principal maneuver in each candidate study. These elements were then sorted into a taxonomy of co-maneuvers. RESULTS: Nearly all eligible RCTs used highly consistent groups of co-maneuvers. These typically began with (1) the use of consensual and clearly stated blood pressure goals; (2) frequent visits in which blood pressure levels were measured and compared with predefined goals; and, if the goal was not attained, (3) modifications to the treatment based on a detailed action plan that included communication of adverse events. Patient education, feedback to clinicians, and interventions for medication adherence were not commonly used among eligible trials. CONCLUSIONS: Clinicians should translate key behavioral co-maneuvers along with clinically proven treatments for hypertension control in diabetes. These co-maneuvers are conceptually similar to collaborative goal setting and action planning interventions used in innovative chronic care programs.
BACKGROUND: Observational studies routinely describe a significant gap between rates of blood pressure control in routine diabetes care compared with those achieved in randomized controlled trials (RCTs). METHODS: We performed a systematic review of the literature to identify co-maneuvers used in RCTs, defined as ancillary activities or agents administered before, during, or immediately after the main agent under investigation (ie, principal maneuver), but not effectively translated to routine diabetes care. We searched multiple databases for RCTs evaluating the efficacy of treatments for hypertension control in adults with type 2 diabetes mellitus. We considered only phase III human studies of interventions that achieved blood pressure control and scrutinized all elements related to the implementation of the principal maneuver in each candidate study. These elements were then sorted into a taxonomy of co-maneuvers. RESULTS: Nearly all eligible RCTs used highly consistent groups of co-maneuvers. These typically began with (1) the use of consensual and clearly stated blood pressure goals; (2) frequent visits in which blood pressure levels were measured and compared with predefined goals; and, if the goal was not attained, (3) modifications to the treatment based on a detailed action plan that included communication of adverse events. Patient education, feedback to clinicians, and interventions for medication adherence were not commonly used among eligible trials. CONCLUSIONS: Clinicians should translate key behavioral co-maneuvers along with clinically proven treatments for hypertension control in diabetes. These co-maneuvers are conceptually similar to collaborative goal setting and action planning interventions used in innovative chronic care programs.
Authors: Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders Journal: JAMA Date: 2003 Apr 23-30 Impact factor: 56.272
Authors: Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn Journal: Lancet Date: 2002-03-23 Impact factor: 79.321
Authors: Norman R C Campbell; Lawrence A Leiter; Pierre Larochelle; Sheldon Tobe; Arun Chockalingam; Richard Ward; Dorothy Morris; Ross Tsuyuki Journal: Can J Cardiol Date: 2009-05 Impact factor: 5.223
Authors: Jeffrey A Cully; Maria E A Armento; Juliette Mott; Michael R Nadorff; Aanand D Naik; Melinda A Stanley; Kristen H Sorocco; Mark E Kunik; Nancy J Petersen; Michael R Kauth Journal: Implement Sci Date: 2012-07-11 Impact factor: 7.327
Authors: George A Samoutis; Elpidoforos S Soteriades; Henri E Stoffers; Theodora Zachariadou; Anastasios Philalithis; Christos Lionis Journal: BMC Health Serv Res Date: 2008-08-27 Impact factor: 2.655
Authors: Avril Mansfield; Jennifer S Wong; Mark Bayley; Lou Biasin; Dina Brooks; Karen Brunton; Jo-Anne Howe; Elizabeth L Inness; Simon Jones; Jackie Lymburner; Ramona Mileris; William E McIlroy Journal: BMC Neurol Date: 2013-07-18 Impact factor: 2.474